15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Heron Therapeuti, 0 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $2.00 to $2.00, so the covering firms are broadly aligned. The average target of $2.00 sits 471% above the current $0.35. The rating mix has stayed broadly stable, with Buy-side ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.03 next quarter toward $-0.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Hold
Strong Buy00%
Buy00%
Hold2100%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Heron Therapeuti.
As of Sep, 0 of 2 firms rate HRTX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HRTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.03
Range $-0.03 – $-0.03 · 2 analysts · +50% YoY
Next period, 2 analysts expect Heron Therapeuti to earn $-0.03 a share (range $-0.03 – $-0.03), versus $-0.02 a year earlier. Full-year consensus is $-0.13, growing to $-0.11 the year after.
REVENUE · NEXT QUARTER
$38.4M
Range $37.9M – $38.9M · 2 analysts · -5% YoY
Revenue is expected to reach $38.4M (range $37.9M – $38.9M), -5.4% year-over-year. Full-year consensus is $148.3M, rising to $145.9M next year.
Top analysts covering Heron Therapeuti
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HRTX.
#1
Serge Belanger
Needham · Rank #105
Hold
No targeton HRTX
Overall win rate
48%
+ Follow
#2
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Hold
No targeton HRTX
Overall win rate
42%
+ Follow
#3
Carl Byrnes
Northland Capital Markets
Buy
$4.00+1041.9% to target
Coverage
—
+ Follow
#4
CD
Clara Dong
Jefferies
Buy
$5.00+1327.3% to target
Coverage
—
+ Follow
HRTX stock forecast FAQ
Is HRTX stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 2 analyst ratings, 0 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover HRTX?+
2 analysts have an active rating on Heron Therapeuti.
Who is the most accurate analyst covering HRTX?+
Among analysts who currently cover HRTX, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #105). Their current call is Hold.
What is Heron Therapeuti's projected EPS for next quarter?+
The consensus estimate is $-0.03 per share (range $-0.03 – $-0.03) across 2 analysts. Full-year EPS is projected at $-0.13, rising to $-0.11 the following year.
How much revenue is Heron Therapeuti expected to report next quarter?+
Consensus revenue is $38.4M (range $37.9M – $38.9M). Full-year revenue is projected at $148.3M, growing to $145.9M next year.
Have analysts been upgrading or downgrading HRTX lately?+
As of Sep, 0 of 2 firms rate HRTX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HRTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
